{"pmid":32449235,"title":"Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab.","text":["Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab.","Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid and tocilizumab.","Transpl Infect Dis","Lauterio, Andrea","Valsecchi, Mila","Santambrogio, Sara","De Carlis, Riccardo","Merli, Marco","Calini, Angelo","Centonze, Leonardo","Buscemi, Vincenzo","Bottiroli, Maurizio","Puoti, Massimo","Fumagalli, Roberto","De Carlis, Luciano","32449235"],"abstract":["Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid and tocilizumab."],"journal":"Transpl Infect Dis","authors":["Lauterio, Andrea","Valsecchi, Mila","Santambrogio, Sara","De Carlis, Riccardo","Merli, Marco","Calini, Angelo","Centonze, Leonardo","Buscemi, Vincenzo","Bottiroli, Maurizio","Puoti, Massimo","Fumagalli, Roberto","De Carlis, Luciano"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449235","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/tid.13334","keywords":["covid-19","coronavirus","immunosuppression","kidney transplantation","pandemic","tocilizumab"],"e_drugs":["Hydroxychloroquine","tocilizumab","lopinavir-ritonavir drug combination","Steroids"],"topics":["Case Report"],"weight":1,"_version_":1667785213899440131,"score":9.490897,"similar":[{"pmid":32354637,"pmcid":"PMC7142878","title":"COVID-19 infection in kidney transplant recipients.","text":["COVID-19 infection in kidney transplant recipients.","By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy.","Kidney Int","Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore","32354637"],"abstract":["By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy."],"journal":"Kidney Int","authors":["Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354637","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.03.018","keywords":["covid-19","sars-cov-2 infection","immunosuppression","kidney transplantation"],"locations":["London","hypoxia","ferritin"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Case Report"],"weight":1,"_version_":1666138495195807744,"score":246.5072},{"pmid":32181990,"title":"Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.","text":["Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.","The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia.","Am J Transplant","Zhu, Lan","Xu, Xizhen","Ma, Ke","Yang, Junling","Guan, Hanxiong","Chen, Song","Chen, Zhishui","Chen, Gang","32181990"],"abstract":["The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia."],"journal":"Am J Transplant","authors":["Zhu, Lan","Xu, Xizhen","Ma, Ke","Yang, Junling","Guan, Hanxiong","Chen, Song","Chen, Zhishui","Chen, Gang"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181990","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1111/ajt.15869","keywords":["covid-19","coronavirus","immunosuppression","pneumonia","renal transplantation"],"e_drugs":["Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666138492545007617,"score":246.13751},{"pmid":32279418,"title":"Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","text":["Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.","Transpl Infect Dis","Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero","32279418"],"abstract":["During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy."],"journal":"Transpl Infect Dis","authors":["Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279418","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/tid.13286","keywords":["covid-19","drug-drug interaction","kidney transplant"],"e_drugs":["Hydroxychloroquine","Steroids","lopinavir-ritonavir drug combination","Tacrolimus"],"topics":["Case Report"],"weight":1,"_version_":1666138491570880516,"score":218.13022},{"pmid":32317180,"pmcid":"PMC7166037","title":"Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.","text":["Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.","BACKGROUND: Previous studies on coronavirus disease 2019 (COVID-19) have focused on populations with normal immunity, but lack data on immunocompromised populations. OBJECTIVE: To evaluate the clinical features and outcomes of COVID-19 pneumonia in kidney transplant recipients. DESIGN, SETTING, AND PARTICIPANTS: A total of 10 renal transplant recipients with laboratory-confirmed COVID-19 pneumonia were enrolled in this retrospective study. In addition, 10 of their family members diagnosed with COVID-19 pneumonia were included in the control group. INTERVENTION: Immunosuppressant reduction and low-dose methylprednisolone therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The clinical outcomes (the severity of pneumonia, recovery rate, time of virus shedding, and length of illness) were compared with the control group by statistical analysis. RESULTS AND LIMITATIONS: The clinical symptomatic, laboratory, and radiological characteristics of COVID-19 pneumonia in the renal transplant recipients were similar to those of severe COVID-19 pneumonia in the general population. The severity of COVID-19 pneumonia was greater in the transplant recipients than in the control group (five severe/three critical cases vs one severe case). Five patients developed transient renal allograft damage. After a longer time of virus shedding (28.4 +/- 9.3 vs 12.2 +/- 4.6 d in the control group) and a longer course of illness (35.3 +/- 8.3 vs 18.8 +/- 10.5 d in the control group), nine of the 10 transplant patients recovered successfully after treatment. One patient developed acute renal graft failure and died of progressive respiratory failure. CONCLUSIONS: Kidney transplant recipients had more severe COVID-19 pneumonia than the general population, but most of them recovered after a prolonged clinical course and virus shedding. Findings from this small group of cases may have important implications for the treatment of COVID-19 pneumonia in immunosuppressed populations. PATIENT SUMMARY: Immunosuppressed transplant recipients with coronavirus disease 2019 infection had more severe pneumonia, but most of them still achieved a good prognosis after appropriate treatment.","Eur Urol","Zhu, Lan","Gong, Nianqiao","Liu, Bin","Lu, Xia","Chen, Dong","Chen, Song","Shu, Hongge","Ma, Ke","Xu, Xizhen","Guo, Zhiliang","Lu, Enfeng","Chen, Dongrui","Ge, Qinggang","Cai, Junchao","Jiang, Jipin","Wei, Lai","Zhang, Weijie","Chen, Gang","Chen, Zhishui","32317180"],"abstract":["BACKGROUND: Previous studies on coronavirus disease 2019 (COVID-19) have focused on populations with normal immunity, but lack data on immunocompromised populations. OBJECTIVE: To evaluate the clinical features and outcomes of COVID-19 pneumonia in kidney transplant recipients. DESIGN, SETTING, AND PARTICIPANTS: A total of 10 renal transplant recipients with laboratory-confirmed COVID-19 pneumonia were enrolled in this retrospective study. In addition, 10 of their family members diagnosed with COVID-19 pneumonia were included in the control group. INTERVENTION: Immunosuppressant reduction and low-dose methylprednisolone therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The clinical outcomes (the severity of pneumonia, recovery rate, time of virus shedding, and length of illness) were compared with the control group by statistical analysis. RESULTS AND LIMITATIONS: The clinical symptomatic, laboratory, and radiological characteristics of COVID-19 pneumonia in the renal transplant recipients were similar to those of severe COVID-19 pneumonia in the general population. The severity of COVID-19 pneumonia was greater in the transplant recipients than in the control group (five severe/three critical cases vs one severe case). Five patients developed transient renal allograft damage. After a longer time of virus shedding (28.4 +/- 9.3 vs 12.2 +/- 4.6 d in the control group) and a longer course of illness (35.3 +/- 8.3 vs 18.8 +/- 10.5 d in the control group), nine of the 10 transplant patients recovered successfully after treatment. One patient developed acute renal graft failure and died of progressive respiratory failure. CONCLUSIONS: Kidney transplant recipients had more severe COVID-19 pneumonia than the general population, but most of them recovered after a prolonged clinical course and virus shedding. Findings from this small group of cases may have important implications for the treatment of COVID-19 pneumonia in immunosuppressed populations. PATIENT SUMMARY: Immunosuppressed transplant recipients with coronavirus disease 2019 infection had more severe pneumonia, but most of them still achieved a good prognosis after appropriate treatment."],"journal":"Eur Urol","authors":["Zhu, Lan","Gong, Nianqiao","Liu, Bin","Lu, Xia","Chen, Dong","Chen, Song","Shu, Hongge","Ma, Ke","Xu, Xizhen","Guo, Zhiliang","Lu, Enfeng","Chen, Dongrui","Ge, Qinggang","Cai, Junchao","Jiang, Jipin","Wei, Lai","Zhang, Weijie","Chen, Gang","Chen, Zhishui"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317180","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.eururo.2020.03.039","keywords":["coronavirus disease 2019","immunosuppression","kidney transplantation","outcome","pneumonia"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Methylprednisolone"],"topics":["Treatment"],"weight":1,"_version_":1666138493650206721,"score":210.21187},{"pmid":32301198,"title":"Case report: A kidney transplant patient with mild COVID-19.","text":["Case report: A kidney transplant patient with mild COVID-19.","Coronavirus Disease 2019 (COVID-19) is currently a pandemic with a mortality rate of 1%-6% in the general population. However, the mortality rate seems to be significantly higher in elderly patients, especially those hospitalized with comorbidities, such as hypertension, diabetes, or coronary artery diseases. Because viral diseases may have atypical presentations in immunosuppressed patients, the course of the disease in the transplant patient population is unknown. Hence, the management of these patients with COVID-19 is an area of interest, and a unique approach is warranted. Here, we report the clinical features and our treatment approach for a kidney transplant patient with a diagnosis of COVID-19. We believe that screening protocols for SARS-Cov-2 should be re-evaluated in patients with solid-organ transplants.","Transpl Infect Dis","Arpali, Emre","Akyollu, Basak","Yelken, Berna","Tekin, Suda","Turkmen, Aydin","Kocak, Burak","32301198"],"abstract":["Coronavirus Disease 2019 (COVID-19) is currently a pandemic with a mortality rate of 1%-6% in the general population. However, the mortality rate seems to be significantly higher in elderly patients, especially those hospitalized with comorbidities, such as hypertension, diabetes, or coronary artery diseases. Because viral diseases may have atypical presentations in immunosuppressed patients, the course of the disease in the transplant patient population is unknown. Hence, the management of these patients with COVID-19 is an area of interest, and a unique approach is warranted. Here, we report the clinical features and our treatment approach for a kidney transplant patient with a diagnosis of COVID-19. We believe that screening protocols for SARS-Cov-2 should be re-evaluated in patients with solid-organ transplants."],"journal":"Transpl Infect Dis","authors":["Arpali, Emre","Akyollu, Basak","Yelken, Berna","Tekin, Suda","Turkmen, Aydin","Kocak, Burak"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301198","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/tid.13296","keywords":["covid-19","sars-cov-2","kidney transplantation"],"topics":["Case Report"],"weight":1,"_version_":1666138494792105987,"score":205.21994}]}